reported side effects of nevirapine
nausea
skin rash
other side effects
severe dermatological reaction
abnormal hepatic function tests
fever
headache
comprehensive list of adverse effects
needed effects
nevirapine
unwanted side effects
medical attention
following side effects
taking nevirapine
check
doctor
following symptoms of overdose
taking nevirapine
emergency help
nevirapine side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
serious adverse effects
nevirapine
serious side effects
hepatitis
hepatic failure
stevens-johnson syndrome
toxic epidermal necrolysis
hypersensitivity reactions
hepatitis/hepatic failure
signs of hypersensitivity
severe rash
rash
fever
general malaise
fatigue
muscle
joint aches
blisters
oral lesions
conjunctivitis
facial edema
eosinophilia
granulocytopenia
lymphadenopathy
renal dysfunction
first weeks of therapy with nevirapine
critical period during which
patients
life-threatening hepatotoxicity
skin reactions
nevirapine
restarted following
restarted following clinical hepatitis
transaminase elevations
rash
other systemic symptoms
following
following severe skin rash
hypersensitivity reactions
side effects
postmarketing experience
use of the immediate-release formulation
rash
including
maculopapular erythematous cutaneous eruptions
pruritus
severe rash
including rash
maculopapular rash
erythema nodosum
erythematous rash
papular rash
skin reaction
stevens-johnson syndrome
drug reaction with eosinophilia
systemic symptoms
frequency
life-threatening skin reactions
including
fatal cases
toxic epidermal necrolysis
allergic dermatitis
common clinical toxicity
rash
rashes
maculopapular erythematous cutaneous eruptions
pruritus
face
trunk
extremities
rash
first weeks of therapy
utilization of the
day lead-in period with immediate-release nevirapine
frequency of rash
clinical trials
grade
rashes
patients
taking immediate-release nevirapine during the first weeks of therapy
grade
rashes
immediate-release nevirapine-treated patients
study
side effects
least moderate intensity
rash
including rash
maculopapular rash
erythema nodosum
erythematous rash
papular rash
skin reaction
stevens-johnson syndrome
drug reaction with eosinophilia
systemic symptoms
patients
immediate-release formulation
patients
extended-release formulation
life-threatening skin reactions
including
fatal cases
cases of stevens-johnson syndrome
toxic epidermal necrolysis
hypersensitivity reactions
rash
constitutional findings
organ dysfunction
women
greater risk of nevirapine-associated rash
rash
half of patients with symptomatic hepatic side effects
elevated sgpt/alt
symptomatic hepatic events
severity
elevated sgot/ast
asymptomatic transaminase elevations
ast
alt
times
upper limit of normal
uln
clinical hepatitis
including hepatitis
hepatotoxicity
acute hepatitis
liver disorder
toxic hepatitis
hepatic failure
jaundice
elevated bilirubin
mg/dl
asymptomatic elevations in gamma-glutamyltransferasefrequency
liver enzyme abnormalities
ast
alt
elevated alkaline phosphatase
life-threatening hepatotoxicity
including
fatal cases
progression
hepatic failure
transaminase elevation
hyperbilirubinemia
hepatic encephalopathy
prolonged partial thromboplastin time
eosinophilia
postmarketing reports
jaundice
cholestatic hepatitis
hepatic necrosis
hepatic failure
risk of symptomatic hepatic events
severity
first weeks
nevirapine groups
controls through weeks of therapy
female gender
higher cd
cell counts at the start of therapy place patients
increased risk of hepatic events
including
fatal events
women with cd
cell counts
cells/mm
including
pregnant women
using nevirapine with other antiretrovirals
hiv
infection
greatest risk
nevirapine-associated hepatotoxicity
genders
cd
cell counts
time during therapy
coinfection with hepatitis b
c
transaminases at the start of nevirapine therapy
greater risk of later symptomatic events
weeks
starting nevirapine
asymptomatic increases in ast
alt
rash
half of patients with symptomatic hepatic side effects
fever
influenza-like symptoms
hepatic events
following
lead-in period
incidence of any hepatic event
immediate-release formulation
extended-release formulation
symptomatic hepatic events
anorexia
jaundice
vomiting
patients
immediate-release
extended-release formulations
incidence of grade
alt/ast elevation
formulation
study
side effects
least moderate intensity
clinical hepatitis
including hepatitis
hepatotoxicity
acute hepatitis
liver disorder
toxic hepatitis
hepatic failure
jaundice
patients
immediate-release formulation
patients
extended-release formulation
controlled studies
liver enzyme abnormalities
ast
alt
patients
receiving nevirapine
elevated sgpt/alt
units/l
immediate-release formulation
grade
sgpt/alt
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
sgpt/alt
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
sgpt/alt
times uln
patients
immediate-release formulation
patients
extended-release formulation
elevated sgot/ast
units/l
immediate-release formulation
grade
sgot/ast
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
sgot/ast
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
sgot/ast
times uln
patients
immediate-release formulation
patients
extended-release formulation
cases
hepatotoxicity
including
cholestatic hepatitis
hepatic necrosis
hepatic failure
cases
patients
nonspecific prodromal signs
symptoms of hepatitis
including fatigue
malaise
anorexia
nausea
jaundice
liver tenderness
abnormal transaminase levels
events
rash
other symptoms
hepatic failure with transaminase elevation
hyperbilirubinemia
hepatic encephalopathy
prolonged partial thromboplastin time
eosinophilia
patients without hiv
using nevirapine for postexposure prophylaxis
reported serious hepatotoxicity
including
hepatic failure
grade
neutrophils
mm
patients
immediate-release formulation
patients
extended-release formulation
grade
neutrophils
mm
patients
immediate-release formulation
patients
extended-release formulation
grade
neutrophils
mm
patients
immediate-release formulation
patients
extended-release formulation
decreased neutrophils
mm
decreased hemoglobin
g/dl
granulocytopenia
severe intensity
decreased platelets
mm
postmarketing reports
anemia
neutropenia
eosinophilia
postmarketing reports
allergic reactions
including anaphylaxis
angioedema
bullous eruptions
ulcerative stomatitis
urticaria
hypersensitivity syndrome
hypersensitivity reactions with rash
constitutional findings
fever
blistering
oral lesions
conjunctivitis
facial edema
muscle
joint aches
general malaise
fatigue
significant hepatic abnormalities
drug reaction with eosinophilia
systemic symptoms
hepatitis
eosinophilia
granulocytopenia
lymphadenopathy
renal dysfunction
decreased phosphate
elevated cholesterol
elevated ldl
frequency
hyperlactatemia
unspecified metabolic alterations
elevated total cholesterol
elevated triglycerides
elevated alkaline phosphatase
acute porphyriapostmarketing reports
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
serum phosphorus
grade
phosphate
patients
immediate-release formulation
patients
extended-release formulation
grade
phosphate
patients
immediate-release formulation
patients
extended-release formulation
grade
phosphate
patients
immediate-release formulation
grade
cholesterol
mg/dl
patients
immediate-release formulation
patients
extended-release formulation
grade
cholesterol
mg/dl
patients
immediate-release formulation
patients
extended-release formulation
grade
ldl
mg/dl
patients
immediate-release formulation
patients
extended-release formulation
grade
ldl
mg/dl
patients
immediate-release formulation
patients
extended-release formulation
nausea
severe intensity
elevated amylase
diarrhea
severe intensity
abdominal pain
severe intensity
frequency
anorexiapostmarketing reports
vomiting
study
side effects
least moderate intensity
diarrhea
immediate-release
abdominal pain
immediate-release
nausea
immediate-release
grade
amylase
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
amylase
times uln
patients
immediate-release formulation
patients
extended-release formulation
grade
amylase
times uln
patients
extended-release formulation
study
side effects
least moderate intensity
fatigue
immediate-release
pyrexia
immediate-release
fever
influenza-like symptoms
hepatic events
fatigue
severe intensity
pyrexia
severe intensity
frequency
fever
asthenia
influenza-like symptomspostmarketing reports
fever
drug withdrawal
result of drug interactions
headache
severe intensity
frequency
neuropathypostmarketing reports
somnolence
paresthesia
study
side effects
least moderate intensity
headache
patients
immediate-release formulation
patients
extended-release formulation
study
side effects
least moderate intensity
arthralgia
patients
immediate-release formulation
patients
extended-release formulation
arthralgia
severe intensity
myalgia
severe intensity
frequency
arthromyalgia
arthritispostmarketing reports
rhabdomyolysis
skin
liver reactions
arthralgia
frequency
immune reconstitution syndrome
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
dry cough
dyspnea
interstitial pulmonary infiltration
frequency
depression
side effects of nevirapine
fda
healthcare professional for medical advice
black, tarry stools
blistering
peeling
loosening of the skin
chills
clay-colored stools
cough
dark urine
diarrhea
fever
general tiredness
weakness
itching
muscle pain
light-colored stools
side pain
nausea and vomiting
difficult urination
pale skin
red, irritated eyes
red skin lesions
purple center
shortness of breath
skin rash
sore throat
sores
ulcers
white spots in the mouth
lips
troubled breathing with exertion
unusual bleeding
bruising
unusual tiredness
weakness
stomach pain
yellow eyes
skin
decreased appetite
hives
loss of appetite
swelling of the feet
lower legs
stomach pain
pain
numbness
tingling of the hands
arms
legs
feet
sleepiness
unusual drowsiness
tingling
burning
prickly sensations
chest pain
cough
decrease in weight
dizziness or lightheadedness
feeling of constant movement of self
surroundings
headache
pain in the ankles
knees
red lumps under the skin
legs
sensation of spinning
trouble sleeping
difficulty with moving
muscle pain
stiffness
pain in the joints